A J van der Wekken - JoVE Visualize

Showing results (1-10 of 16) with videos related to

Pageof 2

Sort By:

Nederlands Tijdschrift Voor Geneeskunde|June 1, 2017

[New biopsy at lung cancer progression: rational treatment of resistant lung cancer]L B M Hijmering-Kappelle, A J van der Wekken, T J N Hiltermann, et al.

Critical Reviews in Oncology/Hematology|February 8, 2016

Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literatureA J van der Wekken, A Saber, T J N Hiltermann, et al.

Clinical Pharmacokinetics|March 5, 2025

Opportunities for Precision Dosing of Cytotoxic Drugs in Non-Small Cell Lung Cancer: Bridging the Gap in Precision MedicineM P Kicken, M J Deenen, A J van der Wekken, et al.

Translational Oncology|June 13, 2026

Real-world evidence of RET fusion prevalence and testing in patients with metastatic non-small cell lung cancerB N Cajiao Garcia, V D de Jager, C C H J Epskamp-Kuijpers, et al.

Lung Cancer (Amsterdam, Netherlands)|October 7, 2024

The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modelingF Zwierenga, L Zhang, J Melcr, et al.

European Journal of Cancer (Oxford, England : 1990)|May 24, 2024

Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the NetherlandsV D de Jager, B N Cajiao Garcia, C C H J Kuijpers, et al.

Lung Cancer (Amsterdam, Netherlands)|January 12, 2020

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancerB van Veggel, J F Vilacha Madeira R Santos, S M S Hashemi, et al.

Lung Cancer (Amsterdam, Netherlands)|February 22, 2023

Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trialH Kievit, M B Muntinghe-Wagenaar, L B M Hijmering-Kappelle, et al.

Plos One|August 31, 2017

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progressionA J van der Wekken, J L Kuiper, A Saber, et al.

JTO Clinical and Research Reports|April 10, 2023

Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLCM Jebbink, A J de Langen, K Monkhorst, et al.

Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:

Pageof 2

Nederlands Tijdschrift Voor Geneeskunde|June 1, 2017

[New biopsy at lung cancer progression: rational treatment of resistant lung cancer]L B M Hijmering-Kappelle, A J van der Wekken, T J N Hiltermann, et al.

Critical Reviews in Oncology/Hematology|February 8, 2016

Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literatureA J van der Wekken, A Saber, T J N Hiltermann, et al.

Clinical Pharmacokinetics|March 5, 2025

Opportunities for Precision Dosing of Cytotoxic Drugs in Non-Small Cell Lung Cancer: Bridging the Gap in Precision MedicineM P Kicken, M J Deenen, A J van der Wekken, et al.

Translational Oncology|June 13, 2026

Real-world evidence of RET fusion prevalence and testing in patients with metastatic non-small cell lung cancerB N Cajiao Garcia, V D de Jager, C C H J Epskamp-Kuijpers, et al.

Lung Cancer (Amsterdam, Netherlands)|October 7, 2024

The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modelingF Zwierenga, L Zhang, J Melcr, et al.

European Journal of Cancer (Oxford, England : 1990)|May 24, 2024

Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the NetherlandsV D de Jager, B N Cajiao Garcia, C C H J Kuijpers, et al.

Lung Cancer (Amsterdam, Netherlands)|January 12, 2020

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancerB van Veggel, J F Vilacha Madeira R Santos, S M S Hashemi, et al.

Lung Cancer (Amsterdam, Netherlands)|February 22, 2023

Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trialH Kievit, M B Muntinghe-Wagenaar, L B M Hijmering-Kappelle, et al.

Plos One|August 31, 2017

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progressionA J van der Wekken, J L Kuiper, A Saber, et al.

JTO Clinical and Research Reports|April 10, 2023

Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLCM Jebbink, A J de Langen, K Monkhorst, et al.

Pageof 2